Inotrem
Created in 2013 by Prof. Sebastien Gibot, Dr. Marc Derive and Dr. Jean-Jacques Garaud, Inotrem is a French biotech company specializing in the discovery and development of novel treatments in the field of inflammatory pathologies with a focus on critical care. The Company’s leading product candidate is a TREM-1 inhibitor that aims to control excessive inflammation in severe sepsis patients. Since its inception, Inotrem has received the initial support of the Incubateur Lorrain and the University of Lorraine in Nancy, Région Lorraine, BPI France and Inserm Transfert.
Sector
Biopharmaceuticals
Strategy
Capital
Status
Live
Website
www.inotrem.com
Related News
Inotrem announces positive outcome of its Phase II ASTONISH trial in septic shock patients demonstrating efficacy of nangibotide
5 Sofinnova Partners portfolio companies selected to French Tech 120
Inotrem Bolsters Leadership Team With the Appointment of Sven Zimmermann as New CEO
Inotrem Receives Clearance From French, Belgian And US Authorities to Launch a Phase II Clinical Trial Aimed at Assessing Nangibotide in Mechanically Ventilated Patients With COVID-19
Inotrem Announces Enrollment of First Patient in its Phase IIb ASTONISH Trial for Nangibotide in the Treatment of Septic Shock
SofinnovaCapital
The Sofinnova Capital Strategy acts as a founding and lead investor in early-stage biopharma and medtech start-ups focusing on groundbreaking therapeutic technologies.
SofinnovaMD Start
The MD Start Strategy is Sofinnova’s in-house medtech accelerator. The team’s hands-on entrepreneurial expertise contributes to the platform's global leadership in company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy supports ground-breaking innovations in later-stage biotech and medtech companies, enabling ambitious life sciences companies to reach their full potential.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy seeks early-stage investments that will have a positive impact on sustainability in the chemicals, agriculture, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy seeks early-stage projects to bring the best Italian science to the world stage.
SofinnovaDigital Medicine
The Sofinnova Digital Medicine Strategy backs early-stage startups at the intersection of biology, data and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is dedicated entirely to the creation and acceleration of European biotech startups, in partnership with leading research organizations.